Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The second riboflavin-binding myeloma IgG lambdaDOT. I. Biochemical and functional characterization.

G Merlini1, R Bruening, R A Kyle

  • 1Cancer Research Center/Institute of Cancer Research, Columbia University, College of Physicians and Surgeons, New York, NY 10032.

Molecular Immunology
|May 1, 1990
PubMed
Summary

A unique human monoclonal antibody, IgGDOT, was identified in a patient with multiple myeloma, exhibiting yellowing of the skin and hair due to its high affinity for riboflavin (vitamin B2). This flavin-binding immunoglobulin demonstrates a strong association with riboflavin, impacting protein stability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors influencing equine embryo outcomes in OPU‑ICSI systems: Insights from a large‑scale program in Brazil.

Journal of equine veterinary science·2026
Same author

Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial.

European journal of neurology·2020
Same author

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Journal of hematology & oncology·2018
Same author

Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.

Leukemia·2016
Same author

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.

Leukemia·2016
Same author

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Leukemia·2014

Area of Science:

  • Immunology
  • Biochemistry
  • Hematology

Background:

  • A rare case of multiple myeloma presented with yellow skin and hair, prompting investigation into the underlying cause.
  • The patient produced a human monoclonal immunoglobulin, termed IgGDOT, with unusual flavin-binding properties.

Observation:

  • The purified IgGDOT protein was visibly bright yellow.
  • Analysis identified the bound ligand as riboflavin and its oxidation products.
  • Competitive binding assays confirmed high specificity for riboflavin over other related flavins and non-flavin compounds.

Findings:

  • The flavin ligand was found to be bound to the antibody both in vivo and in vitro.
  • Removal of bound riboflavin led to irreversible denaturation of the monoclonal protein, indicating its crucial role in maintaining protein structure.

Related Experiment Videos

  • Quantitative analysis revealed specific binding constants and stoichiometry for riboflavin interaction with IgGDOT and its fragment FabDOT.

    • Implications:

    • This discovery highlights a novel association between multiple myeloma and a specific flavin-binding monoclonal antibody.
    • The findings offer insights into the structural and functional consequences of hapten binding to monoclonal antibodies.
    • Further research may explore the clinical significance of such flavin-binding antibodies in related conditions.